Management of common but potentially serious and even fatal side effects of CAR-T cell therapies like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) has come a long way since entering the market. Now, Gilead Sciences, Inc. is piloting a partnership with community oncology centers to do much of the clinical legwork, enabling patients to receive CAR-T therapy closer to home instead of having to travel to academic medical centers.
Inside Gilead’s Community Oncology CAR-T Pilot
Scrip sat down with Kite Pharma EVP Cindy Perettie to talk about the program that Gilead is running with Tennessee Oncology to bring CAR-T therapy into the community setting.
